John Paulson selling at Valeant Pharmaceuticals (T:VRX)

John Paulson, a Director, disposed of 578,665 Common Shares on an indirect ownership basis for registered holder Paulson Partners LP and 24,700 Common Shares on an indirect ownership basis for registered holder Paulson Partners Premium LP at a price of US$14.66 on August 9th, 2017. This represents a $11,237,610 divestment of the company's shares and an account share holdings change of -79.1%.

Valeant Pharmaceuticals is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.